Lurbinectedin is a medication used for the treatment of certain types of cancer, such as small cell lung cancer. However, its potential effects on unborn babies are a concern.

According to the sources provided, there is limited information available on the safety of lurbinectedin during pregnancy. Animal studies have shown adverse effects on fetal development, including increased fetal mortality and malformations. Therefore, it is recommended to avoid using lurbinectedin during pregnancy unless the potential benefits outweigh the risks.

The Mayo Clinic advises that women of childbearing age should use effective contraception during treatment with lurbinectedin and for at least six months after the last dose. It is also recommended to have a negative pregnancy test before starting treatment with lurbinectedin.

The FDA-approved prescribing information for lurbinectedin states that the drug can cause fetal harm and should not be used during pregnancy. It is classified as a Pregnancy Category D drug, which means there is positive evidence of fetal risk based on human data or animal studies. The labeling also advises healthcare providers to inform patients of the potential risk to the fetus and to use effective contraception during treatment.

In summary, based on the available information, lurbinectedin has the potential to cause harm to unborn babies. It is recommended to avoid using this medication during pregnancy unless the potential benefits outweigh the risks. Effective contraception should be used during treatment and for a certain period after the last dose.

Sources:
[1] Drug Patent Watch: Lurbinectedin - https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] Mayo Clinic: Lurbinectedin - https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/precautions/drg-20490804
[3] FDA Label for Lurbinectedin - https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf